Nanthealth Inc Cmn (NH) 13.41 $NH NantHealth Pa
Post# of 273249
Posted On: 09/26/2016 9:18:56 AM
Nanthealth Inc Cmn (NH) 13.41 $NH
NantHealth Partners with Children's Hospital of Orange County to Revolutionize Pediatric Cancer Care Through the Use of GPS Cancer(TM)
BusinessWire - Wed Sep 21, 7:00AM CDT
--Research partnership will provide new hope for an estimated 15,780 children between the ages of birth and 19 years of age who are diagnosed with cancer each year(1)
NH: 13.41 (-0.35)
Phoenix Children's Hospital Selects NantHealth's Molecular Testing Platform and Comprehensive Suite of Software Solutions for Precision Cancer Care
BusinessWire - Wed Sep 07, 7:34AM CDT
--NantHealth's decision support, patient engagement, care coordination, and analytics solutions to help Phoenix Children's advance population health and improve value-based outcomes
NH: 13.41 (-0.35)
NantHealth Reports Strong 2016 Second-Quarter Revenues and Continued Progress on GPS Cancer and NantOS Platform
BusinessWire - Tue Aug 09, 3:15PM CDT
--Total Six-Month Net Revenues More than Doubled to $50.9 Million from $23.5 Million
NH: 13.41 (-0.35)
Medical Product Stocks' Earnings on Aug 9: PEN, STE & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:21AM CDT
We have already seen how the results so far have demonstrated a definite improvement from what we had experienced in the last couple of quarters.
NH: 13.41 (-0.35), STE: 73.12 (-0.78), EGRX: 66.28 (-0.47), PEN: 77.32 (-2.07), OMER: 11.64 (-0.26)
Sanford Health Selects NantHealth's eviti Platform to Deliver Efficient, Evidence-Based Oncology Decision Support for Treatment of Cancer Patients
BusinessWire - Wed Aug 03, 6:00AM CDT
NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that Sanford Health, one of the largest health systems in the nation, has entered into a commercial license agreement for the use of its eviti(R), the evidence-based treatment intelligence and web-based oncology decision support platform, which was recently named #1 Clinical Decision Support solution for 2016 by Black Book Market Research.
NH: 13.41 (-0.35)
NantHealth to Report 2016 Second-Quarter Financial Results and Host Conference Call on Tuesday, August 9
BusinessWire - Tue Aug 02, 5:56AM CDT
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2016 second quarter on Tuesday, August 9, 2016 after market close. NantHealth management will host a conference call that same day at 2 p.m. PT (5 p.m. ET) to review the company's performance and answer questions.
NH: 13.41 (-0.35)
NantHealth Announces Closing of Initial Public Offering
BusinessWire - Tue Jun 07, 4:33PM CDT
NantHealth, Inc. (formerly known as Nant Health, LLC), a next-generation, evidence-based, personalized healthcare company, announced today the closing of its initial public offering of 6,500,000 shares of its common stock at a price to the public of $14.00 per share (which reflects a 1-for-5.5 reverse stock split of NantHealth's common stock effected in connection with the conversion of the company from a limited liability company to a corporation). In addition, NantHealth has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions.
NH: 13.41 (-0.35)
Cancer MoonShot 2020 Announces Breast Cancer Working Group with Multiple Leading Cancer Centers and the Launch of GPS Cancer at ASCO 2016
BusinessWire - Tue Jun 07, 7:00AM CDT
--Key thought leaders to accelerate immunotherapy and precision medicine through GPS Cancer(TM)
NH: 13.41 (-0.35)
NantHealth Announces Commercial Availability of GPS Cancer(TM) and Launch of GPS Cancer Browser on a Secure Mobile Platform at the 2016 American Society of Clinical Oncology Annual Meeting
BusinessWire - Fri Jun 03, 6:00AM CDT
--First cancer test to better inform chemotherapy choice with quantitative measurement of known drug resistance and chemo sensitivity protein biomarkers present in patient's cancer cells
NH: 13.41 (-0.35)
NantHealth Announces Pricing of Initial Public Offering
BusinessWire - Wed Jun 01, 6:27PM CDT
NantHealth, Inc. (formerly known as Nant Health, LLC), a next-generation, evidence-based, personalized healthcare company, announced today the pricing of its initial public offering of 6,500,000 shares of its common stock at a price to the public of $14.00 per share (which reflects a 1-for-5 1Z2 reverse stock split of NantHealth's common stock effected in connection with the conversion of the company from a limited liability company to a corporation). The shares are expected to begin trading on The NASDAQ Global Select Market on June 2, 2016, under the symbol "NH". In addition, NantHealth has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common stock.
NH: 13.41 (-0.35)
NantHealth Partners with Children's Hospital of Orange County to Revolutionize Pediatric Cancer Care Through the Use of GPS Cancer(TM)
BusinessWire - Wed Sep 21, 7:00AM CDT
--Research partnership will provide new hope for an estimated 15,780 children between the ages of birth and 19 years of age who are diagnosed with cancer each year(1)
NH: 13.41 (-0.35)
Phoenix Children's Hospital Selects NantHealth's Molecular Testing Platform and Comprehensive Suite of Software Solutions for Precision Cancer Care
BusinessWire - Wed Sep 07, 7:34AM CDT
--NantHealth's decision support, patient engagement, care coordination, and analytics solutions to help Phoenix Children's advance population health and improve value-based outcomes
NH: 13.41 (-0.35)
NantHealth Reports Strong 2016 Second-Quarter Revenues and Continued Progress on GPS Cancer and NantOS Platform
BusinessWire - Tue Aug 09, 3:15PM CDT
--Total Six-Month Net Revenues More than Doubled to $50.9 Million from $23.5 Million
NH: 13.41 (-0.35)
Medical Product Stocks' Earnings on Aug 9: PEN, STE & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:21AM CDT
We have already seen how the results so far have demonstrated a definite improvement from what we had experienced in the last couple of quarters.
NH: 13.41 (-0.35), STE: 73.12 (-0.78), EGRX: 66.28 (-0.47), PEN: 77.32 (-2.07), OMER: 11.64 (-0.26)
Sanford Health Selects NantHealth's eviti Platform to Deliver Efficient, Evidence-Based Oncology Decision Support for Treatment of Cancer Patients
BusinessWire - Wed Aug 03, 6:00AM CDT
NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that Sanford Health, one of the largest health systems in the nation, has entered into a commercial license agreement for the use of its eviti(R), the evidence-based treatment intelligence and web-based oncology decision support platform, which was recently named #1 Clinical Decision Support solution for 2016 by Black Book Market Research.
NH: 13.41 (-0.35)
NantHealth to Report 2016 Second-Quarter Financial Results and Host Conference Call on Tuesday, August 9
BusinessWire - Tue Aug 02, 5:56AM CDT
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2016 second quarter on Tuesday, August 9, 2016 after market close. NantHealth management will host a conference call that same day at 2 p.m. PT (5 p.m. ET) to review the company's performance and answer questions.
NH: 13.41 (-0.35)
NantHealth Announces Closing of Initial Public Offering
BusinessWire - Tue Jun 07, 4:33PM CDT
NantHealth, Inc. (formerly known as Nant Health, LLC), a next-generation, evidence-based, personalized healthcare company, announced today the closing of its initial public offering of 6,500,000 shares of its common stock at a price to the public of $14.00 per share (which reflects a 1-for-5.5 reverse stock split of NantHealth's common stock effected in connection with the conversion of the company from a limited liability company to a corporation). In addition, NantHealth has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions.
NH: 13.41 (-0.35)
Cancer MoonShot 2020 Announces Breast Cancer Working Group with Multiple Leading Cancer Centers and the Launch of GPS Cancer at ASCO 2016
BusinessWire - Tue Jun 07, 7:00AM CDT
--Key thought leaders to accelerate immunotherapy and precision medicine through GPS Cancer(TM)
NH: 13.41 (-0.35)
NantHealth Announces Commercial Availability of GPS Cancer(TM) and Launch of GPS Cancer Browser on a Secure Mobile Platform at the 2016 American Society of Clinical Oncology Annual Meeting
BusinessWire - Fri Jun 03, 6:00AM CDT
--First cancer test to better inform chemotherapy choice with quantitative measurement of known drug resistance and chemo sensitivity protein biomarkers present in patient's cancer cells
NH: 13.41 (-0.35)
NantHealth Announces Pricing of Initial Public Offering
BusinessWire - Wed Jun 01, 6:27PM CDT
NantHealth, Inc. (formerly known as Nant Health, LLC), a next-generation, evidence-based, personalized healthcare company, announced today the pricing of its initial public offering of 6,500,000 shares of its common stock at a price to the public of $14.00 per share (which reflects a 1-for-5 1Z2 reverse stock split of NantHealth's common stock effected in connection with the conversion of the company from a limited liability company to a corporation). The shares are expected to begin trading on The NASDAQ Global Select Market on June 2, 2016, under the symbol "NH". In addition, NantHealth has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common stock.
NH: 13.41 (-0.35)
(0)
(0)Scroll down for more posts ▼